BioSpace News Archive

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib.

The AmerisourceBergen Foundation , an independent not-for-profit charitable giving organization focused on supporting health-related causes that enrich the global community, has committed $150,000 to the United Nations Foundation ’s Shot@Life campaign to support vaccine equity.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nasdaq has halted trading of the company’s common stock.

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24-months of treatment.

Potrero Medical, announced today that a publication from the Accuryn Registry Study ( NCT04669548 ),"Intra‑abdominal hypertension in cardiac surgery patients: a multicenter observational sub‑study of the Accuryn registry” has been published in The Journal of Clinical Monitoring and Computing.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress TM 2022, to be held in London, UK on June 22-26, 2022.

On June 9, 2022, the Cold Spring Harbor Laboratory Board of Trustees elected Mark L. Claster to the private, not-for-profit institution’s governing body.

Scholar Rock today announced that it has entered into a securities purchase agreement with certain institutional investors to sell, in a registered direct offering, 16,326,530 shares of common stock.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the peer-reviewed journal Science, detailing the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates.

ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for UM171.